Novel Late-Stage Pipeline Products to Enter HD Therapeutics Market, States GlobalData in Its Report Published at MarketPublishers.com
15 Aug 2016 • by Natalie Aster
LONDON – FDA approved treatments for Huntington’s disease (HD) (also termed Huntington's chorea) across the 7MM are very limited, comprising just 2 symptomatic medications, tiapride and tetrabenazine, which are both approved therapies to treat chorea with associated HD. Off-label symptomatic drug products are amid other treatment modalities giving an impetus to the HD therapeutics market; many of them are widely genericized across the 7MM. 4 drugs in the late-stage pipeline – 2 symptomatic therapies, SD-809 (deutetrabenazine) and pridopidine, and 2 potential disease-modifying drugs, PBT2 and RP103 – are anticipated to enter the markets of the USA and 5 countries of the EU in the years to come, and they are set to be a stimulant for the growth in this chronically underserved marketplace. Forecasts say that SD-809 and pridopidine will also be launched in Japan in the upcoming years.
Considerable barriers to the development of the HD market are poised to be the expensiveness of new treatments and potential problems pertaining to reimbursement, which will likely restrain the use of more high-priced drugs.
Furthermore, one of significant unmet need in this field is the identification of a strong HD biomarker for monitoring the progression of the disease alongside determining the effects of therapeutic interventions.
Insightful research report “OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024” prepared by GlobalData offers an all-round, detailed examination of the HBV infection therapeutics marketplace. It provides a careful overview of the disease. The study takes a careful look at the disease; provides annualized revenue of the HD market, annual cost of therapy and therapy usage pattern data from 2014 and to 2024. The study provides insights into the important topics like market characterisation, key unmet needs, R&D and clinical trials assessment, analysis of late-stage clinical studies and an overview of different implications for the HD therapeutics marketplace. The report focuses on the investigation of the 6 HD drugs in the late-stage pipeline, limelighting emerging trends alongside reviewing drugs in earlier-phase trials. Furthermore, it examines the market competition in the world HD therapeutics market and identifies the top players. An insightful, independent assessment of the key industry restraints, drivers and challenges is included. The research study also keeps track of the drug sales in the worldwide HD therapeutics market during 2014-2024.
More studies by our market research partner can be found at GlobalData page.